Real‐world drug survival and reasons for treatment discontinuation of biologics and apremilast in patients with psoriasis in an academic center-Reference-Cited by-同舟云学术

Real‐world drug survival and reasons for treatment discontinuation of biologics and apremilast in patients with psoriasis in an academic center

Published:2021-02-12 Issue:2 Volume:34 Page:
ISSN:1396-0296
Container-title:Dermatologic Therapy
language:en
Short-container-title:Dermatologic Therapy

Author:

Zeb Lawangeen¹²^ORCID,Mhaskar Rahul³,Lewis Suzanna¹,Patel Nishit S.¹,Sadhwani Divya¹,Patel Nupur¹,Ekhlassi Erfon¹,Lu Yuanyuan³,Seminario‐Vidal Lucia¹

Affiliation:

1. Department of Dermatology and Cutaneous Surgery University of South Florida Morsani College of Medicine Tampa Florida USA

2. Department of Internal Medicine University of Florida College of Medicine Gainesville Florida USA

3. Department of Public Health University of South Florida Morsani College of Medicine Tampa Florida USA

Funder

AbbVie

Celgene

Eli Lilly and Company

Novartis

Publisher

Wiley

Subject

Dermatology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dth.14826

Reference9 articles.

1. Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis

2. Drug survival rates and reasons for drug discontinuation in psoriasis

3. Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris

4. A comparison of psoriasis drug failure rates and reasons for discontinuation in biologics vs conventional systemic therapies;Levin AA;J Drugs Dermatol,2014

5. Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-World Data on Brodalumab Treatment in Patients with Moderate-to-Severe Plaque Psoriasis: An Observational Study from the Czech Republic BIOREP Registry;Advances in Therapy;2024-08-29

2. Four‐year drug survival of apremilast in patients with psoriasis;The Journal of Dermatology;2023-03-20

3. Apremilast and biologics: Characteristics of patients treated with apremilast before, during, or after a biological treatment;Dermatologic Therapy;2022-10-07

4. Retrospective study of apremilast drug survival in psoriasis patients in a daily practice setting: A long‐term experience;Dermatologic Therapy;2022-05-24

5. Apremilast survival and reasons for discontinuation in psoriasis: five-year experience from a Greek tertiary care centre;Dermatology Practical & Conceptual;2022-05-02